A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
[my_disclaimer]
Common Conditions Treated with Medical Cannabis in the UK in 2025 – What the Evidence Shows
Since medical cannabis became prescribable in November 2018, private specialist clinics have treated thousands of UK patients for a wide range of conditions — far more than the very narrow list approved for NHS use.
In 2025, the most common conditions seen in private practice include:
- Chronic Pain (by far the #1 reason)
- Neuropathic pain, fibromyalgia, arthritis, back pain, post-surgical pain
- Evidence: Multiple real-world studies and patient registries (e.g., UK Medical Cannabis Registry) show 60–80% of private patients report pain as primary condition.
- Typical products: Balanced THC/CBD oils or flower (THC often helps more than CBD alone for severe pain).
- Access: Almost always private — NHS rarely approves for chronic non-cancer pain.
2. Anxiety Disorders & PTSD
- Generalised anxiety, social anxiety, panic disorder, post-traumatic stress disorder
- Evidence: Emerging real-world data and small trials suggest CBD-dominant products may reduce anxiety symptoms in some patients; THC can worsen anxiety in high doses.
- Typical products: High-CBD/low-THC oils or capsules.
- Access: Private clinics frequently prescribe for treatment-resistant anxiety when SSRIs/therapy have failed.
3. Multiple Sclerosis (MS) Spasticity
- Muscle stiffness, spasms, pain from MS
- Evidence: Sativex (THC/CBD oromucosal spray) is licensed and NICE-approved for MS spasticity. Private prescriptions often use similar unlicensed products.
- Typical products: THC/CBD sprays or oils.
- Access: NHS possible if Sativex criteria met; private more flexible.
4. Epilepsy (beyond NICE-approved types)
- Treatment-resistant epilepsy (other than Dravet/Lennox-Gastaut syndromes where Epidyolex is licensed)
- Evidence: CBD (Epidyolex) licensed for certain rare epilepsies; real-world data shows benefits from full-spectrum CBPMs in broader cases.
- Typical products: High-CBD oils.
- Access: NHS very limited; private clinics prescribe for refractory cases.
5. Endometriosis & Period-Related Pain
- Severe menstrual pain, pelvic pain, associated anxiety/depression
- Evidence: Growing anecdotal and early-study support for THC/CBD products reducing pain and improving quality of life.
- Typical products: Balanced or THC-dominant oils/vapes.
- Access: Entirely private — no NHS approval.
6. ADHA & Autism-Related Symptoms
- Attention difficulties, irritability, sleep issues, anxiety in adults/children
- Evidence: Very preliminary — some private clinics prescribe off-label based on patient reports and small studies.
- Typical products: CBD-dominant or balanced.
- Access: Private only — controversial and not NICE-supported.
7. Insomnia & Sleep Disorders
- Trouble falling/staying asleep, often linked to pain or anxiety
- Evidence: THC can help with sleep onset; CBD may improve sleep quality without sedation.
- Typical products: Night-time THC/CBD oils.
- Access: Private.
8. Other Frequently Mentioned Conditions
- Inflammatory bowel disease (Crohn’s, ulcerative colitis)
- Palliative care symptoms (nausea, appetite, pain)
- Migraine & cluster headaches
- Tourette syndrome
- Depression (treatment-resistant)
NHS vs Private – Quick Comparison (2025)
| Condition | NHS Access (2025) | Private Access (2025) |
|---|---|---|
| Chronic Pain | Extremely rare | Very common |
| Anxiety/PTSD | Not approved | Common |
| MS Spasticity | Possible (Sativex) | Common |
| Epilepsy | Limited (Epidyolex) | Common (broader) |
| Endometriosis | None | Increasing |
| ADHD/Autism | None | Emerging |
Important Notes
- Most private patients have already tried 2+ conventional treatments without success.
- Evidence is still emerging — many uses rely on real-world patient data rather than large RCTs.
- CBPMs carry risks (e.g., dependence, psychiatric effects with high THC, interactions with other meds).
- Driving laws: Strict DVLA rules apply (see separate guide).
Sources
- UK Medical Cannabis Registry patient data (2024–2025 summaries)
- NICE guidelines (CBPMs, Sativex, Epidyolex)
- GMC guidance on unlicensed medicines
- Clinic reports (Releaf, Alternaleaf, Mamedica, Curaleaf, Lyphe)